Matches in SemOpenAlex for { <https://semopenalex.org/work/W2383822011> ?p ?o ?g. }
Showing items 1 to 57 of
57
with 100 items per page.
- W2383822011 abstract "Objective:To evaluate the clinical efficacy and compliance of Ilepcimide monotherapy for treatment of children with partial seizures of epilepsy.Methods:The children with partial seizures of epilepsy from outpatient department of Internal Medicine-Neurology of the first hospital of Jilin university from March to September in 2011 were collected,including 27 children aged 2-5 years old in younger group and 39 children aged 5-15 years old in older group.All the children were treated with Ilepcimide(initial dose: 5 mg·kg-1·d-1),if onset of epilepsy didn't be controlled very well,the dose added every week was less than 5 mg·kg-1·d-1,the target dose was 10 mg·kg-1·d-1,the maximum dose was less than 300 mg/d.All the children were observed for six months,then a self control open study was performed,the cumulative effects during maintenance stage in the two groups were observed,and evaluation of safety was conducted.Results:After three months,the effective rate and control rate in younger group were 62.96% and 40.74%,respectively;the effective rate and control rate in older group were 64.10% and 41.03%,respectively.After six months,the effective rate and control rate in younger group were 77.78% and 48.15%,respectively;the effective rate and control rate in older group were 79.49% and 51.28%,respectively.Before treatment and at four weeks,three and six months after treatment,the indexes of blood routine test,urine routine test,live function detection,renal function detection,blood electrolyte detection,and electrocardiogram were not found with any changes.Among 66 children,15.15%(10 children) of them were found with adverse reactions,the main manifestations included stomach discomfort,poor appetite or nausea,tired,dizzy giddy,and sleepiness.Conclusion:As a new antiepileptics,Ilepcimide has the advantages of good curative effect,larger safety range,less adverse reactions,and good tolerance for treatment of children with partial seizures of epilepsy,which is suitable for the patients combined with diseases of other systems." @default.
- W2383822011 created "2016-06-24" @default.
- W2383822011 creator A5033992113 @default.
- W2383822011 date "2012-01-01" @default.
- W2383822011 modified "2023-09-25" @default.
- W2383822011 title "Study on clinical efficacy and safety of Ilepcimide monotherapy for treatment of children with partial seizures of epilepsy" @default.
- W2383822011 hasPublicationYear "2012" @default.
- W2383822011 type Work @default.
- W2383822011 sameAs 2383822011 @default.
- W2383822011 citedByCount "0" @default.
- W2383822011 crossrefType "journal-article" @default.
- W2383822011 hasAuthorship W2383822011A5033992113 @default.
- W2383822011 hasConcept C118552586 @default.
- W2383822011 hasConcept C126322002 @default.
- W2383822011 hasConcept C16568411 @default.
- W2383822011 hasConcept C187212893 @default.
- W2383822011 hasConcept C197934379 @default.
- W2383822011 hasConcept C2778186239 @default.
- W2383822011 hasConcept C3019985608 @default.
- W2383822011 hasConcept C3020110884 @default.
- W2383822011 hasConcept C71924100 @default.
- W2383822011 hasConceptScore W2383822011C118552586 @default.
- W2383822011 hasConceptScore W2383822011C126322002 @default.
- W2383822011 hasConceptScore W2383822011C16568411 @default.
- W2383822011 hasConceptScore W2383822011C187212893 @default.
- W2383822011 hasConceptScore W2383822011C197934379 @default.
- W2383822011 hasConceptScore W2383822011C2778186239 @default.
- W2383822011 hasConceptScore W2383822011C3019985608 @default.
- W2383822011 hasConceptScore W2383822011C3020110884 @default.
- W2383822011 hasConceptScore W2383822011C71924100 @default.
- W2383822011 hasLocation W23838220111 @default.
- W2383822011 hasOpenAccess W2383822011 @default.
- W2383822011 hasPrimaryLocation W23838220111 @default.
- W2383822011 hasRelatedWork W1179933929 @default.
- W2383822011 hasRelatedWork W1556852132 @default.
- W2383822011 hasRelatedWork W2011578117 @default.
- W2383822011 hasRelatedWork W2048903603 @default.
- W2383822011 hasRelatedWork W2054929522 @default.
- W2383822011 hasRelatedWork W2065010372 @default.
- W2383822011 hasRelatedWork W2125910347 @default.
- W2383822011 hasRelatedWork W2194920214 @default.
- W2383822011 hasRelatedWork W2348006766 @default.
- W2383822011 hasRelatedWork W2348592904 @default.
- W2383822011 hasRelatedWork W2361547856 @default.
- W2383822011 hasRelatedWork W2379165565 @default.
- W2383822011 hasRelatedWork W2550267293 @default.
- W2383822011 hasRelatedWork W2616959026 @default.
- W2383822011 hasRelatedWork W3028741087 @default.
- W2383822011 hasRelatedWork W3029161542 @default.
- W2383822011 hasRelatedWork W3030612225 @default.
- W2383822011 hasRelatedWork W3032252255 @default.
- W2383822011 hasRelatedWork W3032428221 @default.
- W2383822011 hasRelatedWork W2139081102 @default.
- W2383822011 isParatext "false" @default.
- W2383822011 isRetracted "false" @default.
- W2383822011 magId "2383822011" @default.
- W2383822011 workType "article" @default.